Stem Cell Therapy vs. Immunotherapy: What's the Difference, and Which Treats What?

"Stem cells" and "immunotherapy" get used almost interchangeably in casual conversation, clinic marketing, and even some news coverage — but they describe two different branches of medicine with different goals, different cells, and very different regulatory track records. Stem cell therapy is fundamentally about repair: replacing or regenerating damaged tissue. Immunotherapy is fundamentally about recruitment: turning a patient's own immune system into a more effective cancer-fighting force. This article lays out what each field actually does today, why the lines get blurred, and — because this is the detail most people get wrong — why one of the most famous "cell therapies" in modern oncology, CAR-T, isn't a stem cell therapy at all.

The Core Distinction: Repair vs. Recruitment

Stem cell therapy uses cells — such as hematopoietic (blood-forming) stem cells, mesenchymal stem cells (MSCs), or induced pluripotent stem cells (iPSCs) — that can self-renew and, in some cases, develop into other cell types. The goal is typically to rebuild a tissue or system that's been destroyed or damaged: regrowing a patient's blood and immune system after chemotherapy, for instance.

Cancer immunotherapy, by contrast, doesn't aim to regenerate tissue. It aims to help the immune system recognize and destroy cancer cells that have found ways to hide from it. That can mean removing the immune system's "brakes" (checkpoint inhibitors) or genetically re-engineering a patient's own immune cells to hunt a specific cancer target (CAR-T therapy). The starting material for CAR-T is T cells — a mature immune cell type — not stem cells. That single fact is the source of a lot of public confusion, and it's worth sitting with: a genuinely transformative cancer treatment gets called a "stem cell therapy" in casual usage constantly, and it simply isn't one.

Why People Mix Them Up

The confusion is understandable, for a few real reasons. Both fields involve taking living cells out of a patient's body (or a donor's), modifying or processing them, and infusing them back in — so procedurally, a bone marrow transplant and a CAR-T infusion can look similar to a patient sitting in the infusion chair. Both fields are also relatively young, both get covered in the media under broad headlines like "cell therapy breakthrough," and both have produced some of the most dramatic single-patient success stories in modern medicine, which tends to get generalized into "stem cells cure cancer" narratives that aren't accurate. Bone marrow and cord-blood transplants — genuine stem cell procedures — are in fact used to treat certain blood cancers, which adds another real, if narrow, point of overlap between the two fields.

What Stem Cell Therapy Actually Treats Today

The approved, evidence-backed uses of stem cell therapy are narrower than most marketing suggests. According to the FDA, the clearest example is hematopoietic stem cell transplantation — using blood-forming stem cells (from bone marrow, peripheral blood, or umbilical cord blood) to restore a patient's blood and immune system, most often after high-dose chemotherapy or radiation for blood cancers like leukemia and lymphoma. In December 2025, the FDA approved Omisirge (omidubicel-onlv), a cord-blood-derived stem cell therapy for patients with severe aplastic anemia — a good example of the field still advancing within its established lane. A related FDA-approved cell therapy, Ryoncil (remestemcel-L), uses mesenchymal stromal cells specifically for a narrow pediatric indication: steroid-refractory graft-versus-host disease in children.

What stem cell therapy is not currently approved for, per the FDA's own patient-safety guidance, is nearly everything else it gets marketed for: orthopedic complaints like knee and back pain, autoimmune diseases, autism, macular degeneration, Parkinson's and Alzheimer's disease, ALS, multiple sclerosis, stroke recovery, heart disease, COPD, and anti-aging or cosmetic uses. The FDA has repeatedly warned that clinics selling these treatments — often as "your own stem cells" injections — are operating outside approved use, and has documented real harm from unregulated procedures, including blindness, infections, and unwanted tissue growth. This gap between the narrow approved reality and the broad marketed promise is the single most important thing a newcomer to this topic should understand.

What Cancer Immunotherapy Actually Treats Today

Immunotherapy has a wider approved footprint, and it breaks into a few major categories. Checkpoint inhibitors — drugs that block proteins like PD-1, PD-L1, or CTLA-4 that cancer cells exploit to hide from the immune system — are FDA-approved across a genuinely broad range of solid tumors, including melanoma, non-small cell lung cancer, kidney cancer, bladder cancer, head and neck cancer, liver cancer, and Hodgkin lymphoma, among others, according to the National Cancer Institute. These drugs don't work for every patient or every tumor type, and they carry their own risk of serious immune-related side effects, but their reach across cancer types is real and still expanding.

CAR-T cell therapy is more targeted. The FDA has approved several CAR-T products — including Kymriah, Yescarta, Tecartus, Breyanzi, Abecma, and Carvykti — for specific blood cancers: certain forms of B-cell acute lymphoblastic leukemia, non-Hodgkin lymphoma, mantle cell lymphoma, chronic lymphocytic leukemia, and multiple myeloma, per NCI and FDA data. Results in some of these blood cancers have been striking — NCI has cited trial data showing durable remissions in a majority of some treated lymphoma populations, a genuinely remarkable outcome for patients who had exhausted other options. What CAR-T has not yet cracked, despite years of active research, is solid tumors — cancers like breast, lung, or pancreatic cancer — where finding a safe target and getting engineered T cells to work inside the tumor's hostile environment remains an unsolved problem.

Where the Two Fields Actually Meet

There is one legitimate overlap worth naming clearly: a hematopoietic stem cell transplant is sometimes used specifically to treat blood cancer, and immunotherapy is, by definition, cancer-only. So a patient with leukemia might realistically encounter both fields in the same treatment course — a stem cell transplant to rebuild their marrow, and immunotherapy to target the cancer itself. That's a real intersection, not a myth. But it doesn't make the two fields the same thing, any more than surgery and radiation sometimes being combined makes them the same discipline.

Regulatory Status, Side by Side

Both fields sit under FDA oversight, but their approval landscapes look different in shape. Stem cell therapy has a small number of specifically approved products, almost entirely tied to blood-forming stem cells and a couple of narrow MSC indications, alongside decades of established clinical practice in bone marrow/blood stem cell transplantation for blood cancers and immune disorders. Everything marketed outside that lane — most orthopedic, autoimmune, neurological, and anti-aging stem cell offerings — lacks FDA approval, regardless of how a clinic markets it. Immunotherapy has a considerably longer FDA approval list, spanning multiple checkpoint inhibitor drugs approved across dozens of cancer indications and several approved CAR-T products for specific blood cancers, with active clinical trials (listed on ClinicalTrials.gov) working to extend both approaches further.

Bottom Line

Stem cell therapy and cancer immunotherapy are not two names for the same idea — they're two different medical strategies that happen to share the words "cell" and, often, an IV bag. Stem cell therapy tries to rebuild damaged tissue and is FDA-approved mainly for hematopoietic stem cell transplantation and a couple of narrow related indications, with almost everything else still experimental or unapproved. Cancer immunotherapy tries to unleash the immune system against tumors and has a broader, still-growing approval footprint through checkpoint inhibitors and CAR-T cell therapies for specific cancers. Knowing which field a given claim belongs to — and checking it against what's actually FDA-approved — is one of the most useful filters a patient or caregiver can apply when evaluating any "cell therapy" offer.